BACKGROUND: Visfatin [pre-B cell colony- enhancing factor (PBEF)] is a cytokine highly expressed in visceral fat that exhibits insulin-mimetic properties. However, its role in insulin-resistant states, such as in metabolic syndrome (MetS), remains largely unknown. OBJECTIVE: To investigate the possible differences of plasma visfatin levels between obese and overweight subjects with and without MetS. DESIGN AND PATIENTS: Plasma visfatin concentrations were measured with enzyme-linked immunosorbent assay (ELISA) in 28 overweight and obese [body mass index (BMI)>28 kg/m2] subjects with Mets and 28 age- and sex-matched overweight and obese (BMI>28 kg/m2) individuals without MetS (control group). RESULTS: Patients with MetS exhibited significantly elevated waist circumference (WCR ) values, higher blood pressure readings, higher fasting glucose and triglyceride concentrations as well as lower levels of HDL cholesterol (HDL-C) compared with controls. Total and LDL cholesterol (LDL-C) concentrations did not differ significantly between the two groups. Plasma visfatin concentrations were significantly higher in subjects with MetS compared with controls [27 (16- 65) ng/ml vs 19 (10-47) ng/ml, p<0.05]. The same results were observed even after adjustment for age, sex and BMI. Plasma visfatin levels were positively correlated with age (r=0.32, p<0.05), WCR (r=0.31, p<0.05), triglyceride (r=0.59, p<0.01) and glucose (r=0.33, p<0.05) levels and were negatively correlated with HDL-C levels (r=-0.38, p<0.05). Multiple linear regression analysis revealed similar results. CONCLUSION: Plasma visfatin levels are increased in overweight and obese subjects with MetS compared with those individuals who do not fulfil the criteria for the diagnosis of MetS.
BACKGROUND:Visfatin [pre-B cell colony- enhancing factor (PBEF)] is a cytokine highly expressed in visceral fat that exhibits insulin-mimetic properties. However, its role in insulin-resistant states, such as in metabolic syndrome (MetS), remains largely unknown. OBJECTIVE: To investigate the possible differences of plasma visfatin levels between obese and overweight subjects with and without MetS. DESIGN AND PATIENTS: Plasma visfatin concentrations were measured with enzyme-linked immunosorbent assay (ELISA) in 28 overweight and obese [body mass index (BMI)>28 kg/m2] subjects with Mets and 28 age- and sex-matched overweight and obese (BMI>28 kg/m2) individuals without MetS (control group). RESULTS:Patients with MetS exhibited significantly elevated waist circumference (WCR ) values, higher blood pressure readings, higher fasting glucose and triglyceride concentrations as well as lower levels of HDL cholesterol (HDL-C) compared with controls. Total and LDL cholesterol (LDL-C) concentrations did not differ significantly between the two groups. Plasma visfatin concentrations were significantly higher in subjects with MetS compared with controls [27 (16- 65) ng/ml vs 19 (10-47) ng/ml, p<0.05]. The same results were observed even after adjustment for age, sex and BMI. Plasma visfatin levels were positively correlated with age (r=0.32, p<0.05), WCR (r=0.31, p<0.05), triglyceride (r=0.59, p<0.01) and glucose (r=0.33, p<0.05) levels and were negatively correlated with HDL-C levels (r=-0.38, p<0.05). Multiple linear regression analysis revealed similar results. CONCLUSION: Plasma visfatin levels are increased in overweight and obese subjects with MetS compared with those individuals who do not fulfil the criteria for the diagnosis of MetS.
Authors: T D Filippatos; D N Kiortsis; E N Liberopoulos; M Georgoula; D P Mikhailidis; M S Elisaf Journal: Curr Med Res Opin Date: 2005-12 Impact factor: 2.580
Authors: Janin Berndt; Nora Klöting; Susan Kralisch; Peter Kovacs; Mathias Fasshauer; Michael R Schön; Michael Stumvoll; Matthias Blüher Journal: Diabetes Date: 2005-10 Impact factor: 9.461
Authors: Dominik G Haider; Gregor Holzer; Georg Schaller; Daniel Weghuber; Kurt Widhalm; Oswald Wagner; Stylianos Kapiotis; Michael Wolzt Journal: J Pediatr Gastroenterol Nutr Date: 2006-10 Impact factor: 2.839
Authors: Vasilios G Athyros; Dimitri P Mikhailidis; Athanasios A Papageorgiou; Triandafillos P Didangelos; Emmanuel S Ganotakis; Athanasios N Symeonidis; Stella S Daskalopoulou; Anna I Kakafika; Moses Elisaf Journal: Curr Med Res Opin Date: 2004-11 Impact factor: 2.580
Authors: Dominik G Haider; Karin Schindler; Georg Schaller; Gerhard Prager; Michael Wolzt; Bernhard Ludvik Journal: J Clin Endocrinol Metab Date: 2006-01-31 Impact factor: 5.958
Authors: C Santangelo; C Filesi; R Varì; B Scazzocchio; T Filardi; V Fogliano; M D'Archivio; C Giovannini; A Lenzi; S Morano; R Masella Journal: J Endocrinol Invest Date: 2016-06-25 Impact factor: 4.256
Authors: M M Swarbrick; K L Stanhope; I T Austrheim-Smith; M D Van Loan; M R Ali; B M Wolfe; P J Havel Journal: Diabetologia Date: 2008-08-15 Impact factor: 10.122